A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

Score over time

What counts as success

The trial's main goal(s), called the “primary outcome.”

• Incidence of Dose Limiting Toxicities (DLT)

  Measured over: 42 days

• Incidence of DLTs

  Measured over: 21 days post combination administration

• Incidence of Treatment-Emergent Adverse Events (TEAEs)

  Measured over: Through study completion, up to 5 years

• Incidence of Serious Adverse Events (SAEs)

  Measured over: Through study completion, up to 5 years

• Incidence of deaths

  Measured over: Through study completion, up to 5 years

• Incidence of laboratory abnormalities (Grade 3 or higher per National Cancer Institute Common Terminology Criteria for Adverse Events [NCI-CTCAE] version 5.0 [v5.0])

  Measured over: Through study completion, up to 5 years

• Concentrations of REGN5668 in serum when dosed alone and in combination with cemiplimab or ubamatamab

  Measured over: Through study completion, up to 5 years

• Objective Response Rate (ORR) defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (Eisenhauer, 2009) of REGN5668 in combination with cemiplimab, cemiplimab + fianlimab, or ubamatamab (separately by cohort and combination)

  Measured over: Through study completion, up to 5 years

Changes Tremor has spotted